17550-03-7

Usage

Uses

Used in Menopause Treatment:
Tibolone is used as a hormone replacement therapy agent for women experiencing menopausal symptoms. It is effective in treating symptoms such as hot flashes, vaginal dryness, and osteoporosis due to its ability to interact with estrogen, progesterone, and androgen receptors in the body. This interaction helps provide relief from menopausal symptoms and maintain bone density.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, tibolone is used as an active pharmaceutical ingredient in the development of medications for menopausal symptoms. Its multifaceted hormonal effects make it a valuable compound for creating targeted treatments that address the diverse needs of women going through menopause.

Upstream product

• 851-14-9 dl-17α-ethyl-3-methoxyestra-1,3,5(10),8-tetraen-17-ol 
• 1624-62-0 estrone 3-methyl ether 
• 81844-94-2 ((17α,20E)-17-hydroxy-3-methoxy-19-norpregna-1,3,5(10),20-tetraen-21-yl)boronic acid 
• 78479-31-9 17α-(E-2-iodovinyl)-Δ^1,3,5-estratrien-3,17β-diol-3 methyl ester 
• 72-33-3 mestranol 

Downstream Products

• 52-78-8 norethandrolone 

Relevant academic research and scientific papers

Highly Selective Hydrogenation of C═C Bonds Catalyzed by a Rhodium Hydride

Under mild conditions (room temperature, 80 psi of H2) Cp*Rh(2-(2-pyridyl)phenyl)H catalyzes the selective hydrogenation of the C═C bond in α,β-unsaturated carbonyl compounds, including natural product precursors with bulky substituents in the β position and substrates possessing an array of additional functional groups. It also catalyzes the hydrogenation of many isolated double bonds. Mechanistic studies reveal that no radical intermediates are involved, and the catalyst appears to be homogeneous, thereby affording important complementarity to existing protocols for similar hydrogenation processes.

A useful, reliable and safer protocol for hydrogenation and the hydrogenolysis of o-benzyl groups: The in situ preparation of an active Pd 0/C catalyst with well-defined properties

A simple, highly reproducible protocol for the hydrogenation of alkenes and alkynes and for the hydrogenolysis of O-benzyl ethers has been developed. The method features the in situ preparation of an active Pd0/C catalyst from Pd(OAc)2 and charcoal, in methanol. The mild reaction conditions (25°C) and low catalyst loading required (0.025 mol%), as well as the absence of contamination of the product by palladium residues (0/C: It's a kind of magic! A sustainable, simple and highly reproducible protocol for the hydrogenation of alkenes and alkynes (see scheme) and for the hydrogenolysis of O-benzyl ethers has been developed with an in situ generated Pd0/C catalyst. The homemade Pd0/C catalyst allows mild reaction conditions (25°C, 1 atm H2) and low catalyst loading (as low as 0.025 mol%), without any contamination of the product by palladium residues (4 ppb).

ROMPgel-supported tris(triphenylphosphine)rhodium(I) chloride: A selective hydrogenation catalyst for parallel synthesis

ROMPgel-supported tris(triphenylphosphine)rhodium(I) chloride has been prepared and the immobilised catalyst has been effectively employed in selective hydrogenations of a variety of alkenes and terminal alkynes.

Synthesis and evaluation of (17 alpha,20E)-21-[125I]iodo-19-norpregna-1,3,5(10),20-tetraene-3,17 -diol and (17 alpha,20E)-21-[125I]iodo-11 beta-methoxy-19-norpregna-1,3,5(10),20-tetraene-3,17-diol (17 alpha-(iodovinyl)estradiol derivatives) as high specific activity potential radiopharmaceuticals.

Two 17 alpha-[125I]iodovinyl estradiol derivatives 4b,d possessing high specific activity have been prepared and tested as potential radiopharmaceuticals. The use of the 3-acetyl derivatives 2c,e and the replacement of iodine monochloride with sodium iodide and Chloramine-T in THF/phosphate buffer (pH 7.0) permitted us to synthesize no-carrier-added (17 alpha,20E)-21-[125I]iodo-19-norpregna-1,3,5(10),20-tetraene-3,17-d iol (4b) and (17 alpha,20E)-21-[125I]iodo-11 beta-methoxy-19-norpregna-1,3,5(10),20-tetraene-3,17-diol (4d) with 50% radiochemical yield and high purity. Although the specific activity represents only half of the theoretical value in some cases, this modified approach is a substantial improvement over the previously published method. Our preliminary distribution studies indicate that although both 4b and 4d localize in the tissues known to have a large concentration of estrogen receptors, 4d accumulates in higher amounts in target tissues and provides a high target to nontarget ratio.

Synthesis of gon-4-enes

1. A therapeutic composition having progestational activity comprising as active ingredient a 17-aliphatic carboxylic acid ester of 17α-ethynyl-18-methyl-19-nortestosterone and a pharmaceutical carrier for said compound.

Synthesis of 13-alkyl-gon-4-ones

The preparation of 13-methylgon-4-enes and novel 13-polycarbonalkylgon-4-enes by a new total synthesis is described. 13-Alkylgon-4-enes having progestational, anabolic and androgenic activities are prepared by forming a tetracylic gonane structure unsaturated in the 1,3,5(10),9(11) and 14-positions, selectively reducing in the B- and C-rings, and converting the aromatic A-ring compounds so-produced to gon-4-enes by Birch reduction and hydrolysis.